Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Enkele nieuwe ontwikkelingen op jaarlijkse MDS-congres
dec 2025 | Bewegingsstoornissen